Hoth Therapeutics, Inc. (HOTH)

NASDAQ: HOTH · IEX Real-Time Price · USD
3.77
-0.14 (-3.58%)
Dec 5, 2022 3:59 PM EST - Market closed
-3.58%
Market Cap 5.08M
Revenue (ttm) n/a
Net Income (ttm) -11.37M
Shares Out 1.29M
EPS (ttm) -0.53
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Oct 26, 2022
Volume 18,349
Open 3.88
Previous Close 3.91
Day's Range 3.76 - 4
52-Week Range 3.47 - 43.75
Beta 0.76
Analysts Buy
Price Target 25.50 (+576.4%)
Earnings Date Nov 16, 2022

About HOTH

Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory b... [Read more]

Industry Pharmaceuticals
IPO Date Feb 15, 2019
Employees 4
Stock Exchange NASDAQ
Ticker Symbol HOTH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for HOTH stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 576.39% from the latest price.

Price Target
$25.5
(576.39% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001

Clinical trial to begin early 2023 for Cancer patients NEW YORK , Dec. 1, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that...

4 days ago - PRNewsWire

Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements

NEW YORK , Nov. 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced that it received written notice from the NASDAQ Stock Marke...

3 weeks ago - PRNewsWire

Why Is Hoth Therapeutics (HOTH) Stock Up 24% Today?

Hoth Therapeutics (NASDAQ: HOTH ) stock is rising higher on Monday positive results from a Phase 1 clinical trial of BioLexa. BioLexa is a treatment in development at Hoth Therapeutics for mild-to-moder...

1 month ago - InvestorPlace

What's Going On With Hoth Therapeutics Stock? - Hoth Therapeutics (NASDAQ:HOTH)

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher Monday after the company announced positive BioLexa Phase 1b clinical trial results.

1 month ago - Benzinga

HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS

MEETS PRIMARY AND SECONDARY ENDPOINTS SAFETY AND EFFICACY BIOLEXA led to significant improvement in disease severity as measured by SCORAD and EASI Using the EASI scale, 100% of patients showed clinical...

1 month ago - PRNewsWire

Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022

NEW YORK , Oct. 24, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it will effect a 1-for-25 reverse split of its issued a...

1 month ago - PRNewsWire

Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke

TBI is responsible for 2.8 million accidents and emergency department visits annually in the U.S. Global Acute Ischemic Stroke Market $2.7 Billion by 2029 NEW YORK , Sept. 20, 2022 /PRNewswire/ -- Hoth ...

2 months ago - PRNewsWire

Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and ...

Treatment with HT-004 significantly reduced lung inflammation after ovalalbumin (OVA) challenge in an asthma and allergy mouse model NEW YORK , Sept. 6, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NAS...

2 months ago - PRNewsWire

Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference

NEW YORK , Aug. 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced today announced the company will be presenting at the Sido...

3 months ago - PRNewsWire

Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program

Hoth Therapeutics Inc (NASDAQ: HOTH) has announced proof-of-concept data generated using cognitive and behavioral assessments in an Alzheimer's disease mouse model. HT-ALZ is therapeutic in development ...

4 months ago - Benzinga

Why Hoth Therapeutics Shares Are Skyrocketing Today

Hoth Therapeutics Inc (NASDAQ: HOTH) shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer's Disease ...

4 months ago - Benzinga

Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model

Chronic treatment with HT-ALZ (>5 weeks) demonstrated significant improvement in behavioral and cognitive function tests in an Alzheimer's disease (AD) mouse model supporting a positive therapeutic pote...

4 months ago - PRNewsWire

Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule

NEW YORK , June 29, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department...

5 months ago - PRNewsWire

Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with A...

NEW YORK , June 21, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused  biopharmaceutical company,  today announced it has received approval by the Bellberry Human Research E...

5 months ago - PRNewsWire

Hoth Announces Adjournment of Annual Meeting of Shareholders Until June 23, 2022

NEW YORK , June 15, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and co...

5 months ago - PRNewsWire

Hoth Therapeutics Announces Extension of Washington University Alzheimer's Mouse Model Study with Alzheimer's Therape...

The focus of the new studies is to determine a human equivalent dose of HT-ALZ for starting human clinical trials NEW YORK , June 9, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patien...

5 months ago - PRNewsWire

Hoth Therapeutics Announces Preliminary Efficacy Findings From Phase 1b Clinical Trial with Mild to Moderate Atopic D...

The preliminary findings reported include patients that showed improvement in atopic dermatitis symptoms and severity across three efficacy endpoints NEW YORK , May 3, 2022 /PRNewswire/ -- Hoth Therapeu...

7 months ago - PRNewsWire

Hoth Therapeutics Adds New Pipeline Program For Stroke, Brain Injury

Hoth Therapeutics Inc (NASDAQ: HOTH) has added a new asset, HT-TBI, as a novel, point-of-care therapy to treat secondary brain injury resulting from ischemic stroke and traumatic brain injury (TBI).  HT...

7 months ago - Benzinga

Hoth Therapeutics Announces New Pipeline Asset, HT-TBI for Stroke and Traumatic Brain Injury

HT-TBI is a novel, point-of-care drug-device combination product under development for acute treatment of secondary brain injury resulting from ischemic stroke and traumatic brain injury NEW YORK , Apri...

7 months ago - PRNewsWire

Hoth Therapeutics, Inc. Announces Closing of $7.0 Million Underwritten Public Offering Priced At-The-Market

NEW YORK , April 14, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the closing of its previously announced underwritten public...

7 months ago - PRNewsWire

Hoth Therapeutics Announces Acceptance to Present HT-ALZ Proof-of-Concept Alzheimer's Disease Data at the 2022 Alzhei...

Dr. Yuede will present the preclinical Alzheimer's disease mouse model data for exploring HT-ALZ for the treatment of Alzheimer's disease NEW YORK , April 12, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc...

7 months ago - PRNewsWire

Hoth Therapeutics, Inc. Announces Pricing of $7.0 Million Underwritten Public Offering Priced At-The-Market

NEW YORK , April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced the pricing of its underwritten public offering of 8,235,29...

7 months ago - PRNewsWire

Hoth Therapeutics Plunges Afterhours On Secondary Public Offering Of Common Stock

Hoth Therapeutics Inc (NASDAQ: HOTH) says it has commenced an underwritten public offering. Details were not disclosed.

7 months ago - Benzinga

Hoth Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

NEW YORK , April 11, 2022 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has commenced an underwritten public offering. EF Hutton...

7 months ago - PRNewsWire

These 8 Stocks Are Seeing Massive Volume Today

Trading volume is a simple way to measure how much of a security is being traded over a period of time. A high trading volume indicates high buying pressure if the stock is moving higher, or high sellin...

7 months ago - Benzinga